Regeneron Pharmaceuticals share price today
(NASDAQ: REGN)

Name: Regeneron Pharmaceuticals Share Price Today (NASDAQ: REGN) - Regeneron Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Regeneron Pharmaceuticals share price is $694.64 & ₹60,079.41 as on 24 Jan 2025, 2.30 'hrs' IST

$694.64

▲

14.61

(2.15%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Regeneron Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Regeneron Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Regeneron Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Regeneron Pharmaceuticals share price movements

Today's Low: $678.58
Today's High: $695.79
$694.64
2.31%
Downside
Day's Volatility :2.47%
Upside
0.16%
52 Weeks Low: $666.25
52 Weeks High: $1,211.20
$694.64
4.09%
Downside
52 Weeks Volatility :44.99%
Upside
42.65%

Regeneron Pharmaceuticals Returns

Period	Regeneron Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-27.12%	-4.8%	0.0%
6 Months	-36.95%	-5.1%	0.0%
1 Year	-28.33%	2.5%	0.0%
3 Years	12.74%	10.2%	-13.0%

Regeneron Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$680.03
Open	$680.54
Today's High	$695.785
Today's Low	$678.58
Market Capitalization	$75.6B
Today's Volume	$912.1K
52 Week High	$1211.1999
52 Week Low	$666.2485
Revenue TTM	$13.8B
EBITDA	$4.6B
Earnings Per Share (EPS)	$40.42
PE Ratio	17.02
Profit Margin	33.61%
Quarterly Earnings Growth YOY	0.3%
Return On Equity TTM	17.17%

How to invest in Regeneron Pharmaceuticals Stock (REGN) from India?

It is very easy for Indian residents to invest directly in Regeneron Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Regeneron Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Regeneron Pharmaceuticals or REGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Regeneron Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Regeneron Pharmaceuticals shares which would translate to 0.001 fractional shares of Regeneron Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Regeneron Pharmaceuticals, in just a few clicks!

Returns in Regeneron Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

Regeneron Pharmaceuticals investment value today

Current value as on today

₹77,317

Returns

₹22,683

(-22.68%)

Returns from Regeneron Pharmaceuticals Stock

₹26,793 (-26.79%)

Dollar Returns

₹4,109 (+4.11%)

Indian investors sentiment towards Regeneron Pharmaceuticals

14.2%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Investment in Regeneron Pharmaceuticals from India has grown in the last 30 days as on Jan 24, 2025. 14.2% more purchase transactions for Regeneron Pharmaceuticals in the last 30 days versus the previous period.

16%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Regeneron Pharmaceuticals on INDmoney from India has grown in the last 30 days as on Jan 24, 2025. 16% more investors are searching Regeneron Pharmaceuticals in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Regeneron Pharmaceuticals

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	1407	0.00	0.49%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	163	0.00	0.63%
Motilal Oswal S&P 500 Index Fund Direct Growth	908	-26.30	0.15%

Global Institutional Holdings in Regeneron Pharmaceuticals

FMR Inc
9.43%
Vanguard Group Inc
8.48%
BlackRock Inc
7.72%
JPMorgan Chase & Co
6.82%
State Street Corp
4.46%
Capital World Investors
3.91%

Analyst Recommendation on Regeneron Pharmaceuticals

Buy

76%Buy

20%Hold

2%Sell

Based on 34 Wall street analysts offering stock ratings for Regeneron Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 34 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Regeneron Pharmaceuticals

What analysts predicted

Upside of 44.77%

Target:

$1,005.61

Current:

$694.64

Insights on Regeneron Pharmaceuticals

Price Movement
In the last 3 months, REGN stock has moved down by -26.8%
Increasing Revenue
Regeneron Pharmaceuticals, Inc. has experienced a positive trend in its revenue over the last three quarters. Revenue increased from $3.14 billion to $3.72 billion, reflecting an average growth of 8.0% each quarter.
Decreasing Net Profit
Regeneron Pharmaceuticals, Inc. has experienced a decline in net profit over the last two quarters. The net profit fell from $1.43 billion to $1.34 billion, reflecting an average decrease of 6.4% per quarter.
REGN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 43.9% return, outperforming this stock by 72.2%
REGN vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.2% return, outperforming this stock by 85.8%
Price to Sales
Regeneron Pharmaceuticals, Inc. has a Price-to-Sales Ratio of 5.4, meaning that investors are willing to pay $5.4 for every $1 of sales the company generates. In comparison, Alnylam Pharmaceuticals, Inc. has a higher Price-to-Sales Ratio of 16.7, indicating that investors are paying significantly more for each dollar of sales for Alnylam. This suggests that Regeneron's stock may be considered more reasonably priced relative to its sales compared to Alnylam.

Regeneron Pharmaceuticals Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$6.7B	↑ 14.28%
Net Income	$2.4B	↑ 103.95%
Net Profit Margin	36.42%	↑ 16.01%

	FY19	Y/Y Change
Revenue	$7.9B	↑ 17.18%
Net Income	$2.1B	↓ 13.44%
Net Profit Margin	26.91%	↓ 9.51%

	FY20	Y/Y Change
Revenue	$8.5B	↑ 8.06%
Net Income	$3.5B	↑ 66.05%
Net Profit Margin	41.35%	↑ 14.44%

	FY21	Y/Y Change
Revenue	$16.1B	↑ 89.14%
Net Income	$8.1B	↑ 129.86%
Net Profit Margin	50.25%	↑ 8.9%

	FY22	Y/Y Change
Revenue	$12.2B	↓ 24.26%
Net Income	$4.3B	↓ 46.28%
Net Profit Margin	35.64%	↓ 14.61%

	FY23	Y/Y Change
Revenue	$13.1B	↑ 7.76%
Net Income	$4.0B	↓ 8.87%
Net Profit Margin	30.14%	↓ 5.5%

	Q2 FY23	Q/Q Change
Revenue	$3.2B	↓ 0.13%
Net Income	$968.4M	↑ 18.42%
Net Profit Margin	30.66%	↑ 4.8%

	Q3 FY23	Q/Q Change
Revenue	$3.4B	↑ 6.48%
Net Income	$1.0B	↑ 4.07%
Net Profit Margin	29.97%	↓ 0.69%

	Q4 FY23	Q/Q Change
Revenue	$3.4B	↑ 2.13%
Net Income	$1.2B	↑ 15.06%
Net Profit Margin	33.77%	↑ 3.8%

	Q1 FY24	Q/Q Change
Revenue	$3.1B	↓ 8.42%
Net Income	$722.0M	↓ 37.74%
Net Profit Margin	22.96%	↓ 10.81%

	Q2 FY24	Q/Q Change
Revenue	$3.5B	↑ 12.79%
Net Income	$1.4B	↑ 98.38%
Net Profit Margin	40.38%	↑ 17.42%

	Q3 FY24	Q/Q Change
Revenue	$3.7B	↑ 4.89%
Net Income	$1.3B	↓ 6.4%
Net Profit Margin	36.03%	↓ 4.35%

	FY18	Y/Y Change
Profit	$6.3B	↑ 14.64%

	FY19	Y/Y Change
Profit	$7.1B	↑ 12.82%

	FY20	Y/Y Change
Profit	$7.4B	↑ 4.18%

	FY21	Y/Y Change
Profit	$13.6B	↑ 84.82%

	FY22	Y/Y Change
Profit	$10.6B	↓ 22.16%

	FY23	Y/Y Change
Profit	$12.2B	↑ 15.27%

	Q2 FY23	Q/Q Change
Profit	$2.8B	↑ 1.8%

	Q3 FY23	Q/Q Change
Profit	$3.2B	↑ 14.44%

	Q4 FY23	Q/Q Change
Profit	$2.9B	↓ 7.41%

	Q1 FY24	Q/Q Change
Profit	$2.6B	↓ 10.98%

	Q2 FY24	Q/Q Change
Profit	$2.9B	↑ 13.44%

	Q3 FY24	Q/Q Change
Profit	$3.2B	↑ 9.62%

	FY18	Y/Y Change
Operating Cash Flow	$2.2B	↑ 67.94%
Investing Cash Flow	$-1.5B	↑ 45.55%
Financing Cash Flow	$-77.1M	↑ 215.98%

	FY19	Y/Y Change
Operating Cash Flow	$2.4B	↑ 10.7%
Investing Cash Flow	$-2.0B	↑ 38.61%
Financing Cash Flow	$-252.1M	↑ 226.98%

	FY20	Y/Y Change
Operating Cash Flow	$2.6B	↑ 7.74%
Investing Cash Flow	$-70.6M	↓ 96.52%
Financing Cash Flow	$-2.0B	↑ 681.63%

	FY21	Y/Y Change
Operating Cash Flow	$7.1B	↑ 170.47%
Investing Cash Flow	$-5.4B	↑ 7527.05%
Financing Cash Flow	$-1.0B	↓ 48.96%

	FY22	Y/Y Change
Operating Cash Flow	$5.0B	↓ 29.18%
Investing Cash Flow	$-3.8B	↓ 29.72%
Financing Cash Flow	$-1.0B	↑ 0.32%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$1.0B	↓ 25.24%
Investing Cash Flow	$-2.4B	↑ 912.69%
Financing Cash Flow	$-614.2M	↑ 90.45%

Regeneron Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Regeneron Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Regeneron Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Regeneron Pharmaceuticals, Inc.	-5.11%	-36.95%	-28.33%	12.74%	100.35%
Biontech Se	1.23%	34.01%	18.85%	-26.4%	246.9%
Vertex Pharmaceuticals Incorporated	4.23%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.91%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Organization	Regeneron Pharmaceuticals
Employees	14165
CEO	Dr. Leonard S. Schleifer M.D., Ph.D.
Industry	Health Technology

Management People of Regeneron Pharmaceuticals

Name	Title
Dr. Leonard S. Schleifer M.D., Ph.D.	Co-Founder, President, CEO & Co-Chairman
Dr. George D. Yancopoulos M.D., Ph.D.	Co-Founder, President, Chief Scientific Officer & Co-Chairman
Dr. Andrew J. Murphy Ph.D.	Executive Vice President of Research
Mr. Daniel P. Van Plew	Executive VP and GM of Industrial Operations & Product Supply
Mr. Christopher R. Fenimore CPA	Senior VP of Finance & CFO
Ms. Patrice Gilooly	Senior Vice President of Quality Assurance & Operations
Mr. Bob McCowan	Senior VP of IT & Chief Information Officer
Mr. Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis
Mr. Joseph J. LaRosa J.D.	Executive VP, General Counsel & Secretary
Ms. Melissa Lozner	Senior VP & Chief Compliance Officer

Important FAQs about investing in Regeneron Pharmaceuticals (REGN) from India :

What is Regeneron Pharmaceuticals share price today?

Regeneron Pharmaceuticals share price today stands at $694.64, Open: $680.54 ; Previous Close: $680.03 ; High: $695.79 ; Low: $678.58 ; 52 Week High: $1,211.20 ; 52 Week Low: $666.25. The stock opens at $680.54, after a previous close of $680.03. The stock reached a daily high of $695.79 and a low of $678.58, with a 52-week high of $1,211.20 and a 52-week low of $666.25.

Can Indians buy Regeneron Pharmaceuticals shares?

Yes, Indians can invest in the Regeneron Pharmaceuticals (REGN) from India.

With INDmoney, you can buy Regeneron Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Regeneron Pharmaceuticals at zero transaction cost.

How can I buy Regeneron Pharmaceuticals shares from India?

It is very easy to buy Regeneron Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Regeneron Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Regeneron Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Regeneron Pharmaceuticals stocks?

To start investing in Regeneron Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.